Per page discussions (new threads)

Imihuasca

Sun, 30 Jul 2017 23:02:08 +0000

Imihuasca is the creation of new molecules called imines, by combining an aldehyde and an amine/amide.

(More specifically, an aldimine is created, which is simply an imine which is derived from an aldehyde.)

Many aldehydes are highly reactive compounds. Some aldehydes are able to form adducts with amides or amines at room temperature without the need for a catalyst.

The word Imihuasca draws from the word ayahuasca which defines a mix of herbs in which DMT is made orally psychedelic by using enzyme inhibitors. The term Imihuasca was originally coined by the user 'Sativa' (the author)

Example reaction -

N-Benzylidene-N-phenethylamine is an aldimine (an imine which is derived from an aldehyde). It's found naturally in cocoa powders.

N-Benzylidene-N-phenethylamine is a natural adduct created from the alkaloid phenylethylamine and the aldehyde benzaldehyde found in cocoa powder.[1]

1. Ziegleder G, Stojacic E, Stumpf B.;
Occurrence of beta-phenylethylamine and its derivatives in cocoa and cocoa products; Fraunhofer-Institut für Lebensmitteltechnologie und Verpackung, München, Bundesrepublik Deutschland.; Z Lebensm Unters Forsch. 1992 Sep;195(3):235-8.; PubMed PMID: 1413998]

CYP3A4

Tue, 09 Dec 2014 00:36:58 +0000

The Journal of Clinical Pharmacology, 06/20/2011

Malati CY et al. – Fexofenadine pharmacokinetics were unaltered by P ginseng administration. Based on these results, P ginseng appeared to induce CYP3A activity in the liver and possibly the gastrointestinal tract. Patients taking P ginseng in combination with CYP3A substrates with narrow therapeutic ranges should be monitored closely for adequate therapeutic response to the substrate medication.

CYP2C9

Wed, 03 Dec 2014 06:11:39 +0000

Eicosapentaenoic acid on wikipedia says:EPA has an inhibitory effect on CYP2C9 and CYP2C19 hepatic enzymes. At high dose, it may also inhibit the activity of CYP2D6 and CYP3A4, important enzymes involved in drug metabolism.

Sulfotransferase (SULT)

Wed, 03 Dec 2014 02:48:51 +0000

ABSTRACT Safrole, present in mace and its essential oils, causes liver tumours in rodents at high dose levels due to formation of DNA reactive 1'-sulfooxysafrole. The present study identifies malabaricone C as a mace constituent able to inhibit safrole DNA adduct formation at the level of sulfotransferasemediated bioactivation. This inhibition was incorporated into physiologically based biokinetic rat and human models. Dosing safrole at 50 mg/kg body weight and malabaricone C-containing mace extract at a ratio reflecting the relative presence in mace, and assuming 100 or 1% uptake of malabaricone Ccontaining mace extract, the model predicted inhibition of 1'-sulfooxysafrole formation for rats and humans by 90 and 100% or 61 and 91%, respectively. To validate the model, mace extract and safrole were co-administered orally to Sprague-Dawley rats. LC-ECI-MS/MS based quantification of DNA adduct levels revealed a significant (p<0.01) 55% reduction of safrole DNA adduct formation by malabaricone C-containing mace extract in the liver of rats exposed to safrole. The data obtained were used to perform a refined risk assessment of safrole. Overall, the results suggest a lower tumour incidence when safrole would be tested within a relevant food matrix containing sulfotransferase inhibitors compared to dosing pure safrole.

From researchgate